皮肤鳞状细胞癌转移机制的研究进展

doi:10.35541/cjd.20220559

Abstract

Abstract: 【Abstract】 Cutaneous squamous cell carcinoma （cSCC） is the second most common skin tumor, and metastatic cSCC usually has a poor prognosis. Many factors influence the metastasis of cSCC, including primary lesion diameter, anatomical location, immunosuppression, clinical types, depth of tumor invasion, degree of differentiation, and vascular, perineural, and lymphatic invasion. Multiple intracellular signaling pathways drive tumor metastasis, such as Wnt/β-catenin, transforming growth factor β, and the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway. This review discusses the factors influencing cSCC metastasis and the role of the above signaling pathways in the metastatic mechanisms of cSCC, providing new insights for the treatment of metastatic cSCC.

Key words: cutaneous squamous cell carcinoma, metastasis, mechanism, risk factor, signal transduction, pathway

Zhu Ping, Wang Daguang. Metastatic mechanisms of cutaneous squamous cell carcinoma[J]. Chinese Journal of Dermatology, 2025, 58(2): 186-189.doi:10.35541/cjd.20220559

References ［25］

［1］	de Jong E, Lammerts M, Genders RE, et al. Update of advanced cutaneous squamous cell carcinoma［J］. J Eur Acad Dermatol Venereol, 2022,36（Suppl 1）:6⁃10. doi: 10.1111/jdv. 17728.
［2］	Genders RE, Weijns ME, Dekkers OM, et al. Metastasis of cutaneous squamous cell carcinoma in organ transplant recipients and the immunocompetent population: is there a difference? A systematic review and meta⁃analysis［J］. J Eur Acad Dermatol Venereol, 2019,33（5）:828⁃841. doi: 10.1111/jdv.15396.
［3］	Guba M, Graeb C, Jauch KW, et al. Pro⁃ and anti⁃cancer effects of immunosuppressive agents used in organ transplantation［J］. Transplantation, 2004,77（12）:1777⁃1782. doi: 10.1097/01.tp. 0000120181.89206.54.
［4］	Brougham ND, Tan ST. The incidence and risk factors of metastasis for cutaneous squamous cell carcinoma⁃⁃implications on the T⁃classification system［J］. J Surg Oncol, 2014,110（7）:876⁃882. doi: 10.1002/jso.23731.
［5］	Sunkara RR, Sarate RM, Setia P, et al. SFRP1 in skin tumor initiation and cancer stem cell regulation with potential implications in epithelial cancers［J］. Stem Cell Reports, 2020,14（2）:271⁃284. doi: 10.1016/j.stemcr.2019.12.006.
［6］	Parsons MJ, Tammela T, Dow LE. WNT as a driver and dependency in cancer［J］. Cancer Discov, 2021,11（10）:2413⁃2429. doi: 10.1158/2159⁃8290.CD⁃21⁃0190.
［7］	Zimmerli D, Cecconi V, Valenta T, et al. WNT ligands control initiation and progression of human papillomavirus⁃driven squamous cell carcinoma［J］. Oncogene, 2018,37（27）:3753⁃3762. doi: 10.1038/s41388⁃018⁃0244⁃x.
［8］	Dayal J, Mason SM, Salas⁃Alanis JC, et al. Heterogeneous addiction to transforming growth factor⁃beta signalling in recessive dystrophic epidermolysis bullosa⁃associated cutaneous squamous cell carcinoma［J］. Br J Dermatol, 2021,184（4）:697⁃708. doi: 10.1111/bjd.19421.
［9］	Li L, Li F, Xia Y, et al. UVB induces cutaneous squamous cell carcinoma progression by de novo ID4 methylation via methylation regulating enzymes［J］. EBioMedicine, 2020,57:102835. doi: 10. 1016/j.ebiom.2020.102835.
［10］	Ke Y, Wang XJ. TGFβ signaling in photoaging and UV⁃induced skin cancer［J］. J Invest Dermatol, 2021,141（4S）:1104⁃1110. doi: 10.1016/j.jid.2020.11.007.
［11］	Zhang J, Jiang H, Xu D, et al. DNA⁃PKcs mediates an epithelial⁃mesenchymal transition process promoting cutaneous squamous cell carcinoma invasion and metastasis by targeting the TGF⁃β1/Smad signaling pathway［J］. Onco Targets Ther, 2019,12:9395⁃9405. doi: 10.2147/OTT.S205017.
［12］	Wang H, Li H, Yan Q, et al. Serum matrix metalloproteinase⁃13 as a diagnostic biomarker for cutaneous squamous cell carcinoma［J］. BMC Cancer, 2021,21（1）:816. doi: 10.1186/s12885⁃021⁃08566⁃1.
［13］	Taniguchi S, Elhance A, Van Duzer A, et al. Tumor⁃initiating cells establish an IL⁃33⁃TGF⁃β niche signaling loop to promote cancer progression［J］. Science, 2020,369（6501）:eaay1813 ［pii］. doi: 10.1126/science.aay1813.
［14］	Peng D, Fu M, Wang M, et al. Targeting TGF⁃β signal transduction for fibrosis and cancer therapy［J］. Mol Cancer, 2022,21（1）:104. doi: 10.1186/s12943⁃022⁃01569⁃x.
［15］	Mercurio L, Albanesi C, Madonna S. Recent updates on the involvement of PI3K/AKT/mTOR molecular cascade in the pathogenesis of hyperproliferative skin disorders［J］. Front Med （Lausanne）, 2021,8:665647. doi: 10.3389/fmed.2021.665647.
［16］	Hafner C, Landthaler M, Vogt T. Activation of the PI3K/AKT signalling pathway in non⁃melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations［J］. Exp Dermatol, 2010,19（8）:e222⁃227. doi: 10.1111/j.1600⁃0625. 2009.01056.x.
［17］	Thakur MA, Khandelwal AR, Gu X, et al. Inhibition of fibroblast growth factor receptor attenuates UVB⁃induced skin carcino⁃genesis［J］. J Invest Dermatol, 2022,142（11）:2873⁃2884.e7. doi: 10.1016/j.jid.2022.03.036.
［18］	Yu H, Lin L, Zhang Z, et al. Targeting NF⁃κB pathway for the therapy of diseases: mechanism and clinical study［J］. Signal Transduct Target Ther, 2020,5（1）:209. doi: 10.1038/s41392⁃020⁃00312⁃6.
［19］	Mirzaei S, Saghari S, Bassiri F, et al. NF⁃κB as a regulator of cancer metastasis and therapy response: a focus on epithelial⁃mesenchymal transition［J］. J Cell Physiol, 2022,237（7）:2770⁃2795. doi: 10.1002/jcp.30759.
［20］	Ma X, Wu D, Zhang X, et al. microRNA⁃214 prevents traits of cutaneous squamous cell carcinoma via VEGFA and Bcl⁃2［J］. Technol Cancer Res Treat, 2020,19:15330338 20980098. doi: 10.1177/1533033820980098.
［21］	Neagu M, Constantin C, Cretoiu SM, et al. miRNAs in the diagnosis and prognosis of skin cancer［J］. Front Cell Dev Biol, 2020,8:71. doi: 10.3389/fcell.2020.00071.
［22］	Gong ZH, Zhou F, Shi C, et al. miRNA⁃221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN［J］. Cell Mol Biol Lett, 2019,24:9. doi: 10.1186/s11658⁃018⁃0131⁃z.
［23］	Zhou B, Lin W, Long Y, et al. Notch signaling pathway: architecture, disease, and therapeutics［J］. Signal Transduct Target Ther, 2022,7（1）:95. doi: 10.1038/s41392⁃022⁃00934⁃y.
［24］	Di Nardo L, Pellegrini C, Di Stefani A, et al. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies［J］. J Eur Acad Dermatol Venereol, 2020,34（5）:932⁃941. doi: 10.1111/jdv.16098.
［25］	Bednarski IA, Ciążyńska M, Wódz K, et al. Hippo signaling pathway as a new potential target in non⁃melanoma skin cancers: a narrative review［J］. Life （Basel）, 2021,11（7）:680. doi: 10. 3390/life11070680.

[1]	Zhao Lei, Zhou Ming, Quan Xuemei, Cui Aili. Roles of periostin and its associated signaling pathways in keloids [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240063-e20240063.
[2]	Li Ming, Li Yan, Li Linfeng. JAK inhibitors for the treatment of moderate-to-severe atopic dermatitis [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220342-e0220342.
[3]	Wang Feng, Xia Rushan . Roles of melanocyte stem cells in hair follicles in hair graying [J]. Chinese Journal of Dermatology, 2025, 58(2): 182-185.
[4]	Ji Xiang, Zhu Ping, Huang Shudai, Jiang Jiayi, Huang Kaixuan, Li Zhexi, Yang Xi, Wang Daguang. Analysis of risk factors for autoimmune bullous diseases complicated by venous thromboembolism during hospitalization: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 0(2): 20240299-e20240299.
[5]	Zhang Yamei, Liu Guohao, Tao Yue, Bao Jun. Role of JNK/c-Jun signaling pathway mediated by endoplasmic reticulum stress in triptolide-induced apoptosis of melanoma A375 cells in mice [J]. Chinese Journal of Dermatology, 2024, 57(8): 709-714.
[6]	Qu Yuanyuan, Wang Peng, Zhang Jingzhan, Li Tingting, Kang Xiaojing. Role of circRNA 0001400/RELL1 in regulating the activation of mitogen-activated protein kinase signaling pathway during the development of Kaposi′s sarcoma [J]. Chinese Journal of Dermatology, 2024, 57(8): 685-692.
[7]	Wei-Qi REN Ya-Ru ZOU Min PAN. Risk factors for secondary infection in patients with bullous pemphigoid [J]. Chinese Journal of Dermatology, 2024, 57(8): 770-772.
[8]	Feng Mengdi, Wang Wenqing. Regulatory roles of transcription factors and receptors in the pathogenesis of acne [J]. Chinese Journal of Dermatology, 2024, 57(6): 575-578.
[9]	Guo Lan, Jin Hongzhong. Small-molecule/biological agents in the treatment of pruritus [J]. Chinese Journal of Dermatology, 2024, 57(5): 475-478.
[10]	Hou Xiaoyuan, Wu Nanhui, Xu Mingyuan, Liu Yeqiang. A case of granuloma annulare treated with the JAK inhibitor baricitinib [J]. Chinese Journal of Dermatology, 2024, 57(5): 461-462.
[11]	Pei Lu, Zheng Nana, Zeng Rong, Xie Yuanyuan, Xu Haoxiang, Duan Zhimin, Liu Yuzhen, Li Min, . Molecular mechanisms underlying the inflammatory response induced by Cutibacterium acnes biofilms in keratinocytes [J]. Chinese Journal of Dermatology, 2024, 57(4): 302-308.
[12]	Chen Yuhong, Lyu Zhongfa. Regulatory mechanisms underlying the hair cycle [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230226-e20230226.
[13]	Wu Yubing, Wang Xiaoyu, An Binyi, Wu Yingying, Sang Hong, Kong Qingtao, . Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes signaling pathway in the occurrence of psoriasis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230394-e20230394.
[14]	Yuan Liyan, Yu Xiaoling, Wang Xiaohua, Yang Bin. TYK2 inhibitors for plaque psoriasis: mechanism of action and advances in clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220740-e0220740.
[15]	Xu Jingwei, Chen Shuang, Guo Kelei, Han Li, Bian Hua, . MicroRNAs regulating signaling pathways related to systemic scleroderma fibrosis [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230730-e20230730.

Metastatic mechanisms of cutaneous squamous cell carcinoma

PDF

Knowledge

Abstract

Cite this article

share this article

References ［25］

Related Articles 15

Metrics

Comments

Recommended 10